The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma

NCT06378580 | Completed

• 1 other identifier: LGF22H160084
• Study Type: observational
• Target: 72
• Locations: 1 country
• Sites: 1

Brief Summary

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive tumor with a poor prognosis, despite the emergence of chemotherapies, unmet medical needs and limited treatment options still exist for patients with metastatic PDAC (mPDAC). Surufatinib is a small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor (VEGFR) 1, 2, 3, fibroblast growth factor receptor 1 (FGFR1), and colony stimulating factor 1 receptor (CSF-1R), and ex vivo experiments have demonstrated its effect on PC models. A retrospective analysis of patients with PDAC who underwent surufatinib at Zhejiang Cancer Hospital (Hangzhou,China) from July 2022 to July 2023.The database was extracted from the preoperative demographics, blood markers, and surgical pathology information of patients undergoing surufatinib in the investigators' hospital.

Conditions

Pancreatic Cancer

Outcome Measures

Primary Outcomes (1)

• Median progression-free survival

  5 months

Study Arms (2)

Surufatinib combine immune checkpoint inhibitor

Drug: Surufatinib combine immune checkpoint inhibitor

Chemotherapy

Drug: AG/FOLFIRINOX

Interventions

Surufatinib combine immune checkpoint inhibitor DRUG

Before drug use demographics, blood markers, pathology information# and enhanced CT features. Chemotherapy regimens that were combined with surufatinib included AG or FOLFIRINOX regimens. The AG regimen consisted of nab-paclitaxel (125 mg/m2) followed by gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks. The FOLFIRINOX regimen included oxalip

Surufatinib combine immune checkpoint inhibitor

AG/FOLFIRINOX DRUG

Before drug use demographics, blood markers, pathology information# and enhanced CT features. The AG regimen consisted of nab-paclitaxel (125 mg/m2) followed by gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks. The FOLFIRINOX regimen included oxaliplatin (85 mg/m2), irinotecan (180 mg/m2), leucovorin (400 mg/m2), and 5-fluorouracil (400 mg/m2 bolus, 2400 mg/m2 continuous intravenous infusion for 46 hours) every 14 days. Both the AG and FOLFIRINOX regimens required completion of 6 cycles or until disease progression or unacceptable toxicity.

Chemotherapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The patients with mPDAC who received the surufatinib regimen treatment between July 2022 and July 2023 at Zhejiang Cancer Hospital.

You may qualify if:

• (i) were over 18 years old; (ii) had a histological diagnosis of pancreatic adenocarcinoma; (iii) had at least one measurable lesion; (iv) had undergone at least two cycles of surufatinib treatment.

You may not qualify if:

• (i)non-R0 resection; (ii) Combined with other malignant tumors.

Sponsors & Collaborators

• Luo Cong: lead

Study Sites (1)

Zhejiang Province Cancer Hospital

Hangzhou, Zhejiang, 310000, China

Location

Related Publications (1)

• Yang Y, Xie Q, Shang C, Jiang L, Ding G, Long D, Luo C. The prognostic impact of surufatinib for the treatment of advanced pancreatic ductal adenocarcinoma: a single center real-world retrospective study. Front Oncol. 2025 May 20;15:1574934. doi: 10.3389/fonc.2025.1574934. eCollection 2025.

  PMID: 40463875 DERIVED

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Director

Study Record Dates

• First Submitted: April 17, 2024
• First Posted: April 22, 2024
• Study Start: July 1, 2022
• Primary Completion: July 1, 2023
• Study Completion: April 1, 2024
• Last Updated: April 22, 2024

Record last verified: 2024-04

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)